RU2018135967A - Интраназальные фармацевтические композиции на основе бензодиазепина - Google Patents
Интраназальные фармацевтические композиции на основе бензодиазепина Download PDFInfo
- Publication number
- RU2018135967A RU2018135967A RU2018135967A RU2018135967A RU2018135967A RU 2018135967 A RU2018135967 A RU 2018135967A RU 2018135967 A RU2018135967 A RU 2018135967A RU 2018135967 A RU2018135967 A RU 2018135967A RU 2018135967 A RU2018135967 A RU 2018135967A
- Authority
- RU
- Russia
- Prior art keywords
- weight
- methyl
- pharmaceutical composition
- composition according
- diazepam
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 11
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 title 1
- 229940049706 benzodiazepine Drugs 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 16
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 16
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 claims 16
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims 8
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 8
- 229960003529 diazepam Drugs 0.000 claims 8
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 8
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 8
- 206010010904 Convulsion Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161469940P | 2011-03-31 | 2011-03-31 | |
| US61/469,940 | 2011-03-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013148120/15A Division RU2013148120A (ru) | 2011-03-31 | 2012-03-30 | Интраназальные фармацевтические композиции на основе бензодиазепина |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018135967A true RU2018135967A (ru) | 2018-11-14 |
Family
ID=46928023
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018135967A RU2018135967A (ru) | 2011-03-31 | 2012-03-30 | Интраназальные фармацевтические композиции на основе бензодиазепина |
| RU2013148120/15A RU2013148120A (ru) | 2011-03-31 | 2012-03-30 | Интраназальные фармацевтические композиции на основе бензодиазепина |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013148120/15A RU2013148120A (ru) | 2011-03-31 | 2012-03-30 | Интраназальные фармацевтические композиции на основе бензодиазепина |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120252793A1 (enExample) |
| EP (1) | EP2691100A4 (enExample) |
| JP (1) | JP2014509655A (enExample) |
| KR (1) | KR20140029426A (enExample) |
| CN (1) | CN103619338B (enExample) |
| AR (1) | AR085927A1 (enExample) |
| AU (1) | AU2012236334B2 (enExample) |
| BR (1) | BR112013024968A2 (enExample) |
| CA (1) | CA2831308A1 (enExample) |
| MX (1) | MX357800B (enExample) |
| PH (2) | PH12013501915A1 (enExample) |
| RU (2) | RU2018135967A (enExample) |
| SG (2) | SG193958A1 (enExample) |
| TW (1) | TWI601532B (enExample) |
| WO (1) | WO2012135619A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101517415B1 (ko) | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| JP5929800B2 (ja) * | 2012-04-03 | 2016-06-08 | コニカミノルタ株式会社 | 定着液および画像形成方法 |
| AU2018275686B2 (en) * | 2017-06-02 | 2024-02-01 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US12042487B2 (en) | 2018-11-16 | 2024-07-23 | Arcutis Biotherapeutics, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20200155524A1 (en) | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| US20210161870A1 (en) | 2017-06-07 | 2021-06-03 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US12011437B1 (en) | 2017-06-07 | 2024-06-18 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| US11278492B2 (en) | 2018-01-05 | 2022-03-22 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| WO2019182745A1 (en) * | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| MX2020013192A (es) | 2018-06-04 | 2021-08-16 | Arcutis Inc | Metodo y formulacion para mejorar el tiempo de retraso de penetracion en la piel de roflumilast. |
| CN111529489A (zh) * | 2020-04-17 | 2020-08-14 | 山东省药学科学院 | 一种含有地西泮的鼻腔喷雾剂 |
| EP4255393B1 (en) | 2020-12-04 | 2025-05-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having antifungal properties |
| MX2024008192A (es) | 2021-12-28 | 2024-09-10 | Arcutis Biotherapeutics Inc | Espumas en aerosol de roflumilast topico. |
| JP2025530005A (ja) | 2022-09-15 | 2025-09-09 | アーキュティス・バイオセラピューティクス・インコーポレーテッド | ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE229817T1 (de) * | 1996-10-24 | 2003-01-15 | Alza Corp | Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung |
| EP1196156B1 (en) * | 1999-07-26 | 2008-04-30 | SK Holdings Co., Ltd. | Transnasal anticonvulsive compositions |
| DK1539285T4 (da) * | 2002-09-03 | 2012-01-02 | Pharmacure Health Care Ab | Næsesprayer |
| TW200824693A (en) * | 2006-08-28 | 2008-06-16 | Jazz Pharmaceuticals Inc | Pharmaceutical compositions of clonazepam and methods of use thereof |
| US7745430B2 (en) * | 2006-11-15 | 2010-06-29 | Sk Holdings Co., Ltd. | Transnasal anticonvulsive pharmaceutical composition |
| US8946208B2 (en) * | 2007-08-31 | 2015-02-03 | Archimedes Development Limited | Non-aqueous pharmaceutical composition |
| KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| WO2011034920A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
-
2012
- 2012-03-30 RU RU2018135967A patent/RU2018135967A/ru not_active Application Discontinuation
- 2012-03-30 CN CN201280017015.8A patent/CN103619338B/zh active Active
- 2012-03-30 WO PCT/US2012/031453 patent/WO2012135619A2/en not_active Ceased
- 2012-03-30 AU AU2012236334A patent/AU2012236334B2/en not_active Ceased
- 2012-03-30 EP EP12763553.0A patent/EP2691100A4/en not_active Ceased
- 2012-03-30 SG SG2013072319A patent/SG193958A1/en unknown
- 2012-03-30 CA CA2831308A patent/CA2831308A1/en not_active Abandoned
- 2012-03-30 JP JP2014502835A patent/JP2014509655A/ja active Pending
- 2012-03-30 RU RU2013148120/15A patent/RU2013148120A/ru not_active Application Discontinuation
- 2012-03-30 PH PH1/2013/501915A patent/PH12013501915A1/en unknown
- 2012-03-30 MX MX2013011336A patent/MX357800B/es active IP Right Grant
- 2012-03-30 KR KR1020137028968A patent/KR20140029426A/ko not_active Ceased
- 2012-03-30 TW TW101111309A patent/TWI601532B/zh not_active IP Right Cessation
- 2012-03-30 BR BR112013024968A patent/BR112013024968A2/pt not_active Application Discontinuation
- 2012-03-30 US US13/435,837 patent/US20120252793A1/en not_active Abandoned
- 2012-03-30 SG SG10201602176RA patent/SG10201602176RA/en unknown
- 2012-04-03 AR ARP120101144A patent/AR085927A1/es unknown
-
2014
- 2014-01-14 US US14/154,575 patent/US20140128381A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/198,884 patent/US20170151258A1/en not_active Abandoned
-
2017
- 2017-09-15 PH PH12017501688A patent/PH12017501688A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140029426A (ko) | 2014-03-10 |
| SG193958A1 (en) | 2013-11-29 |
| US20140128381A1 (en) | 2014-05-08 |
| RU2013148120A (ru) | 2015-05-10 |
| US20170151258A1 (en) | 2017-06-01 |
| BR112013024968A2 (pt) | 2016-12-20 |
| PH12017501688A1 (en) | 2018-09-10 |
| CA2831308A1 (en) | 2012-10-04 |
| JP2014509655A (ja) | 2014-04-21 |
| MX357800B (es) | 2018-07-25 |
| AU2012236334A1 (en) | 2013-10-10 |
| AU2012236334B2 (en) | 2017-02-16 |
| CN103619338A (zh) | 2014-03-05 |
| HK1195252A1 (zh) | 2014-11-07 |
| EP2691100A4 (en) | 2014-09-24 |
| WO2012135619A3 (en) | 2012-11-22 |
| MX2013011336A (es) | 2013-12-16 |
| AR085927A1 (es) | 2013-11-06 |
| US20120252793A1 (en) | 2012-10-04 |
| SG10201602176RA (en) | 2016-04-28 |
| TWI601532B (zh) | 2017-10-11 |
| TW201302204A (zh) | 2013-01-16 |
| EP2691100A2 (en) | 2014-02-05 |
| CN103619338B (zh) | 2016-06-22 |
| PH12013501915A1 (en) | 2019-11-29 |
| WO2012135619A2 (en) | 2012-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018135967A (ru) | Интраназальные фармацевтические композиции на основе бензодиазепина | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| JP2014509655A5 (enExample) | ||
| IN2014MN01755A (enExample) | ||
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
| PH12014502524B1 (en) | Carboxylic acid compounds | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| EA201591195A1 (ru) | Новые хинолоновые производные | |
| HRP20171175T1 (hr) | Novi triciklički spojevi | |
| PL2629754T3 (pl) | Kompozycja farmaceutyczna w postaci ciekłej do podawania składników czynnych | |
| MX354102B (es) | Derivados de bencimidazol-prolina. | |
| IL217052A0 (en) | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them | |
| WO2012021715A3 (en) | Stable formulations of linaclotide | |
| WO2011146583A3 (en) | Nanoparticulate cinacalcet formulations | |
| WO2013188283A8 (en) | Topical ophthalmological pharmaceutical composition containing sunitinib | |
| ME02576B (me) | Derivati tetrahidropirolotiazina kao inhibitori bace | |
| EP2723177A4 (en) | ADMINISTRATION OF PARAFFINOUS COMPOSITIONS TO THE ROOT TISSUE OF PLANTS | |
| EP3228311A3 (en) | Pharmaceutical and nutraceutical compositions of abscisic acid | |
| EA201492091A1 (ru) | Фармацевтические композиции для местного применения, содержащие тербинафид и мочевину | |
| WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
| RU2016132762A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| HRP20171693T1 (hr) | Farmaceutski pripravak koji sadrži (1r, 4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i ibuprofen | |
| MY185947A (en) | A pharmaceutical composition containing candesartan cilexetil and amlodipine | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150331 |